Demonstrating that this co-regulatory mechanism is relevant in a prostate cancer setting required a prostate cancer cell line with stable knockdown of FKBP52 protein in which to assess β-catenin effects on AR activity in the presence or absence of significant levels of FKBP52. Here, FKBP4 is linked to prostate carcinoma.